HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy.

Abstract
Three treatment programs for Stage I and II mediastinal Hodgkin disease (established by laparotomy) were compared. Involved-field radiotherapy + MOPP gave a disease-free survival rate of 97%, significantly different from 62% and 55% for involved and extended fields, respectively. Corresponding survival figures of 97%, 88%, and 84% were not significantly different statistically due to salvage with radiotherapy and/or chemotherapy. Among patients given radiotherapy alone, the survival figure of 94% for limited mediastinal disease was significantly better than 63% for extensive mediastinal and hilar disease; corresponding disease-free figures of 72% and 35% were also significantly different. Constitutional symptoms were an important prognostic factor in disease-free survival following the use of involved fields; hilar disease was important only with large mediastinal masses. Most relapses were intrathoracic; MOPP alone salvaged only 47%. Treatment of Stage I and II Hodgkin disease should be based on symptoms, extent of mediastinal disease, and hilar involvement.
AuthorsF B Hagemeister, L M Fuller, J A Sullivan, L North, W Velasquez, F G Conrad, P McLaughlin, J J Butler, C C Shullenberger
JournalRadiology (Radiology) Vol. 141 Issue 3 Pg. 783-9 (Dec 1981) ISSN: 0033-8419 [Print] United States
PMID6895415 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Prednisone
Topics
  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Therapy, Combination
  • Female
  • Hodgkin Disease (mortality, therapy)
  • Humans
  • Male
  • Mechlorethamine (therapeutic use)
  • Mediastinal Neoplasms (mortality, therapy)
  • Neoplasm Staging
  • Prednisone (therapeutic use)
  • Procarbazine (therapeutic use)
  • Prognosis
  • Radiotherapy (methods)
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: